SCHEMBL10003409

SCHEMBL10003409

CCc1nc2c(cc1-c1ccc(C)cc1)c(OCC(F)(F)F)c(C(=O)O)n2C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIA2 P42262 3/20 0.36
▸ GRIA4 P48058 3/20 0.36
▸ KDM4E B2RXH2 2/20 0.35
▸ CCKAR P32238 1/20 0.35
▸ PTGER1 P34995 1/20 0.33
▸ SCN9A Q15858 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HCRTR1 O43613 1/20 0.33
▸ HCRTR2 O43614 1/20 0.33
▸ RXRA P19793 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ RORC P51449 1/20 0.33
▸ LTB4R Q15722 1/20 0.32
▸ GABRA2 P47869 1/20 0.32
▸ GABRB2 P47870 1/20 0.32
▸ PIK3CA P42336 1/20 0.32
▸ DPP4 P27487 1/20 0.32
▸ DPP8 Q6V1X1 1/20 0.32
▸ DPP9 Q86TI2 1/20 0.32
▸ AKR1C3 P42330 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003383 0.92 ALPI (0.35) SCN9ARXRAL3MBTL1
SCHEMBL10003244 0.92 PTPN11 (0.39) SCN9ARORCLTB4R
SCHEMBL10002905 0.92 GRIA2 (0.38) GRIA2GRIA4SCN9AALDH1A1RXRA
SCHEMBL10003096 0.92 GRIA2 (0.35) GRIA2GRIA4KDM4ESCN9AALDH1A1
SCHEMBL10003970 0.91 GRIA2 (0.37) GRIA2GRIA4KDM4EALDH1A1RORC
SCHEMBL10003955 0.90 ALDH1A1 (0.40) KDM4ECCKARALDH1A1L3MBTL1GABRA2
SCHEMBL10003500 0.90 PTPN11 (0.41) GRIA2GRIA4KDM4EPTGER1SCN9A
SCHEMBL10003154 0.90 PDE3B (0.38) KDM4ESCN9AALDH1A1RXRAL3MBTL1
SCHEMBL10003659 0.89 RXRA (0.35) GRIA2GRIA4SCN9ARXRAL3MBTL1
SCHEMBL10003313 0.88 PRKAB2 (0.37) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH GRIA2 3298/4885GRIA4 2962/4885KDM4E 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback